880348-24-3

Upstream product

• 583-68-6 2-bromo-p-toluidine 
• 329218-12-4 3-bromo-4-chloro-benzyl alcohol 
• 42860-10-6 3-bromo-4-chlorobenzoic acid 
• 57310-39-1 2-bromo-1-chloro-4-methylbenzene 

Downstream Products

• 1297552-67-0 tert-butyl 3-(3-bromo-4-chlorophenyl)-2,2-dimethylpropanoate 
• 1297551-31-5 (+/-)-tert-butyl 2-[3-(benzylamino)-4-chlorobenzyl]-2-methylbutanoate 
• 1297551-32-6 (+/-)-tert-butyl 2-(3-amino-4-chlorobenzyl)-2-methylbutanoate 
• 1297551-29-1 (+/-)-tert-butyl 2-(3-bromo-4-chlorobenzyl)-2-methylbutanoate 
• 1297551-48-4 (+/-)-tert-butyl 3-(3-bromo-4-chlorophenyl)-2-cyclobutylpropanoate 
• 249647-28-7 3-bromo-4-chlorobenzyl cyanide 

Relevant academic research and scientific papers

AMINO ALCOHOL COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Design, synthesis and structure–activity relationships of novel phenylalanine-based amino acids as kainate receptors ligands

A new series of carboxyaryl-substituted phenylalanines was designed, synthesized and pharmacologically characterized in vitro at native rat ionotropic glutamate receptors as well as at cloned homomeric kainate receptors GluK1–GluK3. Among them, six compounds bound to GluK1 receptor subtypes with reasonable affinity (Kivalues in the range of 4.9–7.5?μM). A structure–activity relationship (SAR) for the obtained series, focused mainly on the pharmacological effect of structural modifications in the 4- and 5-position of the phenylalanine ring, was established. To illustrate the results, molecular docking of the synthesized series to the X-ray structure of GluK1 ligand binding core was performed. The influence of individual substituents at the phenylalanine ring for both the affinity and selectivity at AMPA, GluK1 and GluK3 receptors was analyzed, giving directions for future studies.

N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present application relates to novel substituted 2-(piperidin-1-yl)acetamide derivatives, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular diseases.

Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof

The present application relates to novel substituted 1-benzylcycloalkylcarboxylic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF

The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

PYRIMIDINYL PYRAZOLES AS INSECTICIDES AND PARASITICIDE ACTIVE AGENTS

The present invention relates to pyrimidinylpyrazoles and their use as insecticides, and also to processes for their preparation and to compositions comprising such arylpyrazoles.